Protective effect of bioactive ceramics on liver injury: regulation of pro-inflammatory cytokins expression.
OBJECTIVE
A bioactive ceramics has been reported to regulate the expression of inflammatory cytokines in macrophage cells activated by lipopolysaccharides (LPS). In present study, we investigated the anti-inflammatory effect of bioactive ceramics using liver injury model in mouse.


METHODS
Mice were divided into three groups: Normal group, LPS group (LPS and no ceramics treatment), Ceramics group (LPS and ceramics treatment).


RESULTS
LPS administration induced the increase of plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in mouse. The losses of cytoplasm of hepatocytes due to LPS caused the increase of AST and ALT in mouse plasma. In Ceramics group, however, the concentration of AST and ALT were much lower than LPS group until 6 weeks. And the losses of cytoplasm were rarely seen in Ceramics group. RT-PCR results showed that the decrease of proinflammatory cytokines such as IL-1beta and IL-6 was observed in Ceramics group. Moreover, TGF-beta1 and VEGF expression was increased in Ceramics group.


CONCLUSIONS
Bioactive ceramics effectively protected endotoxin-induced liver injury by attenuation of inflammatory processes in mice.
Lee
Tae-Sung
TS
Research Institute of Biomedical Engineering, School of Medicine, Catholic University of Daegu, Daegu, South Korea.
Park
Kwan-Kyu
KK
Kim
Kyung-Hyun
KH
Chu
Young-Ae
YA
Jeon
Jae-Pil
JP
Hwang
Meeyul
M
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001483:Base Sequence; D001672:Biocompatible Materials / Q000737:chemistry* / Q000494:pharmacology; D002516:Ceramics / Q000737:chemistry* / Q000494:pharmacology; D016207:Cytokines / Q000235:genetics*; D017931:DNA Primers / Q000235:genetics; D018836:Inflammation Mediators / Q000378:metabolism; D008070:Lipopolysaccharides / Q000633:toxicity; D008099:Liver / Q000187:drug effects / Q000293:injuries* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008422:Materials Testing; D051379:Mice; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015533:Transcriptional Activation / Q000187:drug effects
D001672:Biocompatible Materials; D016207:Cytokines; D017931:DNA Primers; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
J Biomed Mater Res. 1973;7(3):25-42
4123968
Science. 2002 Feb 8;295(5557):1014-7
11834817
J Hepatol. 2002 Nov;37(5):678-80
12399237
Science. 1984 Nov 9;226(4675):630-6
6093253
Rheumatol Int. 2005 Dec;26(2):168-72
15965635
Altern Med Rev. 2002 Aug;7(4):328-35
12197784
Ann N Y Acad Sci. 1988;523:54-71
2837945
Science. 1990 Sep 21;249(4975):1431-3
1698311
Arch Biochem Biophys. 2003 Mar 1;411(1):63-72
12590924
J Biomed Mater Res A. 2007 Mar 1;80(3):513-9
17133451
Immunopharmacology. 1995 Apr;29(3):187-205
7542643